Picard Medical Reports Reduced Losses in Q3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy PMI?
Source: NASDAQ.COM
Financial Performance: Picard Medical, Inc. reported a narrowed loss per share of $0.19 in Q3, compared to $0.87 the previous year, while revenue increased to $1.19 million from $0.88 million.
EBIT and EBITDA Losses: The EBIT loss widened to $10.43 million from $6.21 million, but the EBITDA loss narrowed to $3.49 million from $4.44 million year-over-year.
Market Reaction: In pre-market trading, shares of Picard Medical fell by 3.69%, trading at $2.3500 on the New York Stock Exchange.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Facing Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. is facing allegations of false statements regarding a supposed collaboration with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
- Plug Power Lawsuit: Plug Power, Inc. is accused of overstating the availability of funds related to a DOE loan during the class period from January 17 to November 13, 2025, potentially forcing the company to pivot to smaller projects, with a lead plaintiff deadline of April 3, 2026.
- Picard Medical Lawsuit: Picard Medical, Inc. faces allegations of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, failing to disclose insider trading activities, with a lead plaintiff deadline of April 3, 2026.
- BlackRock TCP Capital Lawsuit: BlackRock TCP Capital Corp. is accused of failing to appropriately value investments during the class period from November 6, 2024, to January 23, 2026, leading to an overstated net asset value, with a lead plaintiff deadline of April 6, 2026.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. (NASDAQ:RR) faces a class action lawsuit for failing to disclose its non-existent collaboration with Microsoft during the class period from January 27 to January 29, 2026, with a lead plaintiff motion deadline of April 3, 2026, for affected investors.
- Picard Medical Allegations: Picard Medical, Inc. (NYSE:PMI) is implicated in a class action lawsuit for a fraudulent stock promotion scheme involving social media misinformation during the period from September 2 to October 31, 2025, requiring investors to act by April 3, 2026, to participate.
- Plug Power Misrepresentation: Plug Power, Inc. (NASDAQ:PLUG) is accused in a class action lawsuit of materially overstating the availability of funds from a DOE loan during the class period from January 17 to November 13, 2025, with a deadline for lead plaintiff motions set for April 3, 2026.
- Legal Firm Advisory: The Law Offices of Frank R. Cruz remind affected investors that participation in these class actions does not require immediate action, but they are encouraged to consult legal counsel to understand their rights and interests.
See More
Picard Medical Investors Advised on Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Picard Medical investors about a class action lawsuit for those who purchased securities between September 5 and October 31, 2025, with a deadline for lead plaintiff motions set for April 3, 2026, highlighting the urgency of the legal risks facing the company.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since declined to approximately $2.00, indicating a severe loss of investor confidence and financial instability.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose its involvement in a fraudulent stock promotion scheme driven by social media misinformation and impersonated financial professionals, leading to artificial price inflation and subsequent collapse, revealing significant governance and transparency issues.
- Legal Support: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to pursue claims for losses incurred due to corporate wrongdoing, indicating a potential avenue for recovery for affected investors.
See More
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Picard Medical, urging investors who suffered losses between September 2 and October 31, 2025, to contact them before the April 13, 2026 deadline to discuss their legal rights.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a staggering drop of $7.89 or approximately 59.8% in a single day, marking one of the most significant declines since the company's IPO.
- False Promotion Allegations: The complaint alleges that Picard and its executives violated federal securities laws by engaging in a fraudulent stock promotion scheme involving misinformation on social media and insider trading, severely impacting investor confidence and the company's reputation.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information, including whistleblowers and former employees, to contact the firm to ensure that investors can recover their losses in the class action lawsuit.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiation: A class action lawsuit has been filed against Picard Medical, Inc. (NYSE:PMI) for issuing false and misleading statements during the period from September 2 to October 31, 2025, with investors having until April 3, 2026, to apply as lead plaintiffs, indicating significant legal risks that could impact the company's stock price and market trust.
- Legal Representation Background: The lawsuit is spearheaded by Wolf Haldenstein Adler Freeman & Herz LLP, a firm established in 1888 that specializes in protecting investor rights and boasts over 125 years of experience in securities litigation, underscoring its expertise and credibility in handling such cases.
- Investor Rights Protection: The allegations suggest that Picard Medical failed to disclose material adverse facts that could significantly affect investors, potentially leading to claims for damages from affected investors and exacerbating the company's trust crisis among stakeholders.
- Legal Timeline Framework: Investors must file their applications to become lead plaintiffs by April 3, 2026, highlighting the urgency of the legal process and its potential implications for the company's future operations.
See More
Class Action Lawsuit Announced for Picard Medical, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Picard Medical securities between September 2 and October 31, 2025, with a deadline of April 13, 2026, for those wishing to serve as lead plaintiff, highlighting the urgency and significance of the case.
- Lawsuit Background: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts regarding its business and securities trading during the class period, misleading investors and potentially impacting the company's reputation and stock price.
- Investor Rights Protection: Investors participating in the class action are entitled to compensation without any out-of-pocket costs, indicating a risk-free opportunity for affected investors to seek redress, which may encourage broader participation.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Multiple Companies Facing Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. is facing allegations of false statements regarding a supposed collaboration with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
- Plug Power Lawsuit: Plug Power, Inc. is accused of overstating the availability of funds related to a DOE loan during the class period from January 17 to November 13, 2025, potentially forcing the company to pivot to smaller projects, with a lead plaintiff deadline of April 3, 2026.
- Picard Medical Lawsuit: Picard Medical, Inc. faces allegations of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, failing to disclose insider trading activities, with a lead plaintiff deadline of April 3, 2026.
- BlackRock TCP Capital Lawsuit: BlackRock TCP Capital Corp. is accused of failing to appropriately value investments during the class period from November 6, 2024, to January 23, 2026, leading to an overstated net asset value, with a lead plaintiff deadline of April 6, 2026.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. (NASDAQ:RR) faces a class action lawsuit for failing to disclose its non-existent collaboration with Microsoft during the class period from January 27 to January 29, 2026, with a lead plaintiff motion deadline of April 3, 2026, for affected investors.
- Picard Medical Allegations: Picard Medical, Inc. (NYSE:PMI) is implicated in a class action lawsuit for a fraudulent stock promotion scheme involving social media misinformation during the period from September 2 to October 31, 2025, requiring investors to act by April 3, 2026, to participate.
- Plug Power Misrepresentation: Plug Power, Inc. (NASDAQ:PLUG) is accused in a class action lawsuit of materially overstating the availability of funds from a DOE loan during the class period from January 17 to November 13, 2025, with a deadline for lead plaintiff motions set for April 3, 2026.
- Legal Firm Advisory: The Law Offices of Frank R. Cruz remind affected investors that participation in these class actions does not require immediate action, but they are encouraged to consult legal counsel to understand their rights and interests.
See More
Picard Medical Investors Advised on Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Picard Medical investors about a class action lawsuit for those who purchased securities between September 5 and October 31, 2025, with a deadline for lead plaintiff motions set for April 3, 2026, highlighting the urgency of the legal risks facing the company.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since declined to approximately $2.00, indicating a severe loss of investor confidence and financial instability.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose its involvement in a fraudulent stock promotion scheme driven by social media misinformation and impersonated financial professionals, leading to artificial price inflation and subsequent collapse, revealing significant governance and transparency issues.
- Legal Support: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to pursue claims for losses incurred due to corporate wrongdoing, indicating a potential avenue for recovery for affected investors.
See More
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Picard Medical, urging investors who suffered losses between September 2 and October 31, 2025, to contact them before the April 13, 2026 deadline to discuss their legal rights.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a staggering drop of $7.89 or approximately 59.8% in a single day, marking one of the most significant declines since the company's IPO.
- False Promotion Allegations: The complaint alleges that Picard and its executives violated federal securities laws by engaging in a fraudulent stock promotion scheme involving misinformation on social media and insider trading, severely impacting investor confidence and the company's reputation.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information, including whistleblowers and former employees, to contact the firm to ensure that investors can recover their losses in the class action lawsuit.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiation: A class action lawsuit has been filed against Picard Medical, Inc. (NYSE:PMI) for issuing false and misleading statements during the period from September 2 to October 31, 2025, with investors having until April 3, 2026, to apply as lead plaintiffs, indicating significant legal risks that could impact the company's stock price and market trust.
- Legal Representation Background: The lawsuit is spearheaded by Wolf Haldenstein Adler Freeman & Herz LLP, a firm established in 1888 that specializes in protecting investor rights and boasts over 125 years of experience in securities litigation, underscoring its expertise and credibility in handling such cases.
- Investor Rights Protection: The allegations suggest that Picard Medical failed to disclose material adverse facts that could significantly affect investors, potentially leading to claims for damages from affected investors and exacerbating the company's trust crisis among stakeholders.
- Legal Timeline Framework: Investors must file their applications to become lead plaintiffs by April 3, 2026, highlighting the urgency of the legal process and its potential implications for the company's future operations.
See More
Class Action Lawsuit Announced for Picard Medical, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Picard Medical securities between September 2 and October 31, 2025, with a deadline of April 13, 2026, for those wishing to serve as lead plaintiff, highlighting the urgency and significance of the case.
- Lawsuit Background: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts regarding its business and securities trading during the class period, misleading investors and potentially impacting the company's reputation and stock price.
- Investor Rights Protection: Investors participating in the class action are entitled to compensation without any out-of-pocket costs, indicating a risk-free opportunity for affected investors to seek redress, which may encourage broader participation.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
